BioSpace News Archive

Ensoma /en’sōmə/ is derived from the Greek phrase “en soma,” meaning in the body. We develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within.

At Idorsia US, we are bringing innovative medicines from bench to bedside. With commercial operations based outside of Philadelphia, PA, our goal is to build the commercial footprint that will deliver Idorsia’s deep pipeline of products from its R&D engine to the US market – with the potential to change the lives of many patients.

The mission of the Allen Institute is to unlock the complexities of bioscience and advance our knowledge to improve human health. Using an open science, multi-scale, team approach, the Allen Institute focuses on accelerating foundational research, developing standards and models, and cultivating new ideas to make a broad, transformational impact on science.

SIO Gene Therapies is no longer operating as of April 2023.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together.

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy.

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients.

Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. 

Scorpius BioManufacturing is a CDMO with integrated solutions for large molecule cGMP manufacturing, process and analytical method development, product characterization, and release testing needs. Scorpius’ facility in San Antonio, TX has capacity for both mammalian and microbial clinical manufacturing projects.

AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs.